Less Ads, More Data, More Tools Register for FREE

Pin to quick picksORPH.L Regulatory News (ORPH)

  • There is currently no data for ORPH

Form 8 (OPD)

17 Dec 2019 16:36

RNS Number : 2213X
Open Orphan PLC
17 December 2019
 

The Form 8 announcement released on 17/12/19 at 10:19 under RNS No 0632X has been amended.

 

The full amended text is shown below.

 

Open Orphan plc

 

("Open Orphan" or the "Company")

 

Disclosure under rule 8.1 and 8.2 of the Takeover Code

 

In accordance with Takeover code rule 8.1, the Company makes the following announcement:

 

 

FORM 8 (OPD)

 

PUBLIC OPENING POSITION DISCLOSURE BY A PARTY TO AN OFFER

Rules 8.1 and 8.2 of the Takeover Code (the "Code")

 

1. KEY INFORMATION

 

(a) Full name of discloser:

Open Orphan plc

(b) Owner or controller of interests and short positions disclosed, if different from 1(a):

The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.

N/A

(c) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

Open Orphan plc

(d) Is the discloser the offeror or the offeree?

OFFEROR

(e) Date position held:

The latest practicable date prior to the disclosure

13 December 2019

(f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?

If it is a cash offer or possible cash offer, state "N/A"

NO

 

 

 

2. POSITIONS OF THE PARTY TO THE OFFER MAKING THE DISCLOSURE

 

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

 

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates

 

Class of relevant security:

 

Ordinary Shares of 0.1p each

 

 

Interests

Short positions

Number

%

Number

%

(1) Relevant securities owned and/or controlled:

None

None

(2) Cash-settled derivatives:

 

None

None

(3) Stock-settled derivatives (including options) and agreements to purchase/sell:

None

None

 

TOTAL:

None

None

 

All interests and all short positions should be disclosed.

 

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

 

Details of any securities borrowing and lending positions or financial collateral arrangements should be disclosed on a Supplemental Form 8 (SBL).

 

(b) Rights to subscribe for new securities

 

Class of relevant security in relation to which subscription right exists:

None

Details, including nature of the rights concerned and relevant percentages:

None

 

 

3. POSITIONS OF PERSONS ACTING IN CONCERT WITH THE PARTY TO THE OFFER MAKING THE DISCLOSURE

 

Details of any interests, short positions and rights to subscribe (including directors' and other employee options) of any person acting in concert with the party to the offer making the disclosure:

 

Details of Concert Party shareholdings:

 

Current

% of current total

Raglan Road Capital Limited

21,536,124

8.46%

Pamela Iver

14,880,721

5.85%

Horizon Medical Technologies Limited

4,630,136

1.82%

Anthony Richardson

16,313,388

6.41%

Brendan Buckley

7,845,860

3.08%

Crow Rock Capital Limited

7,845,860

3.08%

Dairine Dempsey

3,138,344

1.23%

Ian O'Connell

3,138,344

1.23%

Montana Capital Limited

1,376,466

0.54%

Clydagh Limited

1,376,466

0.54%

Pat O'Neill

1,569,172

0.62%

McNolan Ventures Limited

470,974

0.19%

Carol Dalton

313,983

0.12%

Bridget Chisolm

313,983

0.12%

Ross Crocket

313,983

0.12%

Dennis Jennings

1,003,332

0.39%

Tom Tierney

2,006,665

0.79%

Mount Amber International Limited

5,016,291

1.97%

Francoise Richardson

1,805,136

0.71%

Gary Duffy

539,654

0.21%

 

 

 

Details of concert party options/warrants:

 

Options over Open Orphan shares

Raglan Road Capital Limited

3,250,000

Cathal Friel CMF Pension Fund

657,285

Dan Cronin

539,654

Michael Fleming

269,866

Pa Nolan

269,866

Maurice Treacy*

7,716,964

 

Details of Director shareholdings (excluding those in the Concert Party)

 

Options over Open Orphan shares

Michael Ryan

134,586

 

 

Details of Director options (excluding those in the Concert Party)

 

Options over Open Orphan shares

Grant date

Exercise price per share (pence)

Expiry date

Christian Milla

770,000

14/09/2017

13

13/09/2027

Michael Ryan

200,000

14/09/2017

13

13/09/2027

 

*Maurice Treacy's options were granted on 28/06/2019, with an exercise price per share of 5.6 pence and expiry date of 27/06/2022

 

 

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

 

Details of any securities borrowing and lending positions or financial collateral arrangements should be disclosed on a Supplemental Form 8 (SBL).

 

4. OTHER INFORMATION

 

(a) Indemnity and other dealing arrangements

 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the party to the offer making the disclosure or any person acting in concert with it:

Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state "none"

 

None

 

 

(b) Agreements, arrangements or understandings relating to options or derivatives

 

Details of any agreement, arrangement or understanding, formal or informal, between the party to the offer making the disclosure, or any person acting in concert with it, and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state "none"

 

None

 

 

(c) Attachments

 

Are any Supplemental Forms attached?

 

Supplemental Form 8 (Open Positions)

NO

Supplemental Form 8 (SBL)

NO

 

 

Date of disclosure:

17 December 2019

Contact name:

Cathal Friel, Chief Executive Officer

Telephone number:

+353 (0)1 644 0007

 

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

 

The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.

 

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
FEEFMMMZVNFGLZM
Date   Source Headline
11th Jun 20207:00 amRNSMajor New Contract Signed
10th Jun 20205:40 pmRNSHolding(s) in Company
10th Jun 20205:35 pmRNSHolding(s) in Company
10th Jun 20205:30 pmRNSHolding(s) in Company
4th Jun 20207:00 amRNSLaunch of Covid-19 Antibody Testing
29th May 20208:00 amRNSEuronext Growth Dublin Notice
22nd May 202010:53 amRNSResults of Fundraising
22nd May 20207:01 amRNSPrimaryBid.com Offer
22nd May 20207:00 amRNSProposed Fundraising to raise up to £12 million
18th May 20209:05 amRNSSecond Price Monitoring Extn
18th May 20209:00 amRNSPrice Monitoring Extension
18th May 20207:00 amRNSUpdate on antibody test and share price movement
11th May 20207:00 amRNSAppointment of Joint Broker
11th May 20207:00 amRNSNew COVID-19 Antibody Testing Partnership
4th May 20207:00 amRNSMajor New Contract and Directorate Change
23rd Apr 20207:00 amRNSTesting of anti-viral for treating COVID-19
14th Apr 20202:06 pmRNSSecond Price Monitoring Extn
14th Apr 20202:01 pmRNSPrice Monitoring Extension
23rd Mar 20204:43 pmRNSSecond Price Monitoring Extn
23rd Mar 20204:37 pmRNSPrice Monitoring Extension
20th Mar 20202:06 pmRNSSecond Price Monitoring Extn
20th Mar 20202:00 pmRNSPrice Monitoring Extension
16th Mar 20207:00 amRNSPublication of positive results in journal
12th Mar 20203:32 pmRNSHolding(s) in Company
12th Mar 20209:00 amRNSHolding(s) in Company
12th Mar 20208:00 amRNSEuronext Growth Dublin Notice
10th Mar 20207:00 amRNSPublication of Positive Results in Journal
9th Mar 20204:53 pmRNSCompletion of Compulsory Acquisition of Shares
9th Mar 20207:00 amRNSCoronavirus Challenge Study Model
6th Mar 20207:00 amRNSNew Contract
3rd Mar 20208:00 amRNSEuronext Growth Dublin Notice
2nd Mar 20203:25 pmRNSChange in Registered Office
27th Feb 20207:00 amRNSAppointment of new Director
26th Feb 20203:04 pmRNSResult of Rule 15 Offer and Total Voting Rights
21st Feb 20207:00 amRNSInvestor Event Attendance and Presentation
20th Feb 20207:00 amRNSAppointment of Chair of Advisory Board
20th Feb 20207:00 amRNSAppointment of Chair of Advisory Board
13th Feb 20207:00 amRNSAppointment of Group Chief Financial Officer
11th Feb 20208:00 amRNSEuronext Growth Dublin Notice
10th Feb 202011:17 amRNSValue the Markets Webinar
7th Feb 20206:08 pmRNSHolding(s) in Company
7th Feb 20203:42 pmRNSSignificant shareholder
7th Feb 20207:00 amRNSInvestor Event Attendance and Presentation
6th Feb 20209:30 amRNSTotal Voting Rights
6th Feb 20208:00 amRNSEuronext Growth Dublin Notice
6th Feb 20207:00 amRNSUpcoming Investor Events
5th Feb 202011:00 amRNSExercise of Warrants and Issue of Shares
3rd Feb 202010:30 amRNSNew Corporate Presentation
31st Jan 202011:23 amRNSResults of Placing and Subscription
31st Jan 20207:00 amRNSProposed Placing to raise a minimum of £5 million

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.